Long-acting atypical antipsychotics for the management of schizophrenia - Certificate of Completion

Duration

2 hrs

Profession

Physician

# of Credits

4.0

Accreditation

Certificate of Completion

Expiry Date

2019-08-01

Schizophrenia is a severe mental disorder characterised by profound disrupted thinking and perception. It affects more than 21 million people worldwide and has a prevalence of around 2 per 1000 Australians aged 18 to 45 years. GPs have a key role in managing people with schizophrenia, as at least one third of people with schizophrenia in Australia are being managed by their GP alone.

This interactive online learning activity is valued at 2 Hour(s) of continuing education.

Nagesh Pai,
MBBS, MD, FRANZCP, DPM, DNB Psych,
GradCert Hlth Serv R&D, Grad Cert Med Ed
Professor of Psychiatry, University of Wollongong
Senior Clinical Academic & Professor of Psychiatry, Illawarra
Shoalhaven Local Health District, Wollongong, New South Wales

Dr. Nick Carr,
MA MMed MB BChir DCH MRCGP FRACGP
Clinical Senior Lecturer, University of Melbourne, Victoria

Sharon Locke,
B Nursing
Credentialed Mental Health Nurse
Brisbane, Queensland

On completion of this program, participants will be better able to:

  1. Recall the mechanism of action of atypical antipsychotic medications, including paliperidone palmitate, in the management of schizophrenia
  2. Describe the role of long-acting atypical antipsychotics in the management of schizophrenia
  3. Identify patients who may be suitable for long-acting atypical antipsychotic medications
  4. Counsel patients with schizophrenia and their carers on the benefits of long-acting therapy, including paliperidone palmitate, and proactively address any safety concerns


Related Courses